ALK and neoplasm: For example, we identified the need to increase the gap-in-therapy window from 120 to 180 days by plotting the gap between successive prescriptions, excluding several protein kinase inhibitors as exceptions to the rule for gap-in-therapy line advancement (these -tinib drugs target tumor mutations such as EGFR and ALK genomic aberrations).